propranolol

Trade name: inderal

Small moleculeapproved

Approved

Nov 13, 1967

Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Propranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Also is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; for the prophylaxis of common migraine headache. In addition, is used to improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Due to the high penetration across the blood–brain barrier, propranolol causes sleep disturbances such as insomnia and vivid dreams, and nightmares. Dreaming (rapid eye movement sleep, REM) was reduced and increased awakening. — NCATS

Clinical trial activity

321 trials · 270 clinical orgs · 56 marketing orgs

Phase 1
59
Phase 2
138
Phase 3
54
Phase 4
51

Earliest trial started Sep 1, 1977 (NCT00000493)

Timeline

1960s

  1. Nov 13, 1967

    Earliest FDA Approval

  2. Nov 13, 1967

    Wyeth — NDA Secondary Org

  3. Nov 13, 1967

    Baxalta — NDA Secondary Org

1970s

  1. Sep 4, 1973

    Akrimax Pharmaceuticals — NDA Secondary Org

  2. Jan 1, 1977

    Earliest Phase 3 Sponsor(trial)

  3. Jun 15, 1979

    American Home Products — Marketing Organization

1980s

  1. Apr 19, 1983

    Ani Pharmaceuticals — NDA Secondary Org

  2. Apr 19, 1983

    Ani Pharmaceuticals — Marketing Organization

  3. Jul 3, 1985

    American Home Products — NDA Secondary Org

  4. Jul 30, 1985

    DAVA Pharmaceuticals — Marketing Organization

  5. Aug 6, 1985

    Schering — Marketing Organization

  6. Aug 6, 1985

    Schering-Plough — Marketing Organization

  7. Sep 9, 1985

    Duramed Research — Marketing Organization

  8. Oct 22, 1985

    ANDA Repository — Marketing Organization

  9. Oct 22, 1985

    Innogenix — Marketing Organization

  10. Nov 19, 1985

    Mylan — Marketing Organization

  11. Apr 11, 1986

    Teva — Marketing Organization

  12. Apr 14, 1986

    Vintage — Marketing Organization

  13. Apr 14, 1986

    Endo Pharmaceuticals — Marketing Organization

  14. Apr 14, 1986

    PH HEALTH — Marketing Organization

  15. Apr 18, 1986

    Watson Pharmaceuticals — Marketing Organization

  16. May 15, 1986

    Actavis — Marketing Organization

  17. Jul 7, 1986

    Boehringer Ingelheim — Marketing Organization

  18. Aug 4, 1986

    Amici — Marketing Organization

  19. Oct 22, 1986

    Par Pharmaceuticals — Marketing Organization

  20. Oct 22, 1986

    Strides Pharma Science — Marketing Organization

  21. Oct 22, 1986

    AiPing Pharm Inc — Marketing Organization

  22. Jan 1, 1987

    Earliest Phase 2 Sponsor(trial)

  23. Apr 1, 1987

    Rising Pharmaceuticals — Marketing Organization

  24. May 5, 1987

    Interpharm — Marketing Organization

  25. May 15, 1987

    Roxane Laboratories — Marketing Organization

  26. May 15, 1987

    West-Ward Pharmaceutical — Marketing Organization

  27. Jan 26, 1988

    Warner Chilcott — Marketing Organization

  28. Apr 6, 1988

    Impax Laboratories — Marketing Organization

  29. Jun 8, 1988

    Superpharm — Marketing Organization

  30. Apr 11, 1989

    Inwood Laboratories — Marketing Organization

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Aug 29, 2000

    Athenex, Inc. — Marketing Organization

  2. Aug 29, 2000

    Chartwell Pharmaceuticals — Marketing Organization

  3. Aug 31, 2001

    Fresenius — Marketing Organization

  4. Feb 26, 2003

    Fosun — Marketing Organization

  5. Feb 26, 2003

    Allied Pharmaceutical Services — Marketing Organization

  6. Jan 26, 2007

    Nortec Dev Assoc — Marketing Organization

  7. Feb 15, 2007

    EXTROVIS — Marketing Organization

  8. Jan 10, 2008

    Northstar Healthcare — Marketing Organization

  9. Jan 31, 2008

    Hikma — Marketing Organization

  10. Jun 2, 2008

    IPCA Laboratories Ltd. — Marketing Organization

  11. Mar 6, 2009

    Upsher-Smith Laboratories — Marketing Organization

2010s

  1. Mar 25, 2011

    Zydus Discovery DMCC — Marketing Organization

  2. Jul 15, 2011

    R.P. Scherer — Marketing Organization

  3. Jul 15, 2011

    Adare Pharmaceuticals — Marketing Organization

  4. Mar 14, 2014

    Pierre Fabre — NDA Secondary Org

  5. Mar 14, 2014

    Pierre Fabre — Marketing Organization

  6. Mar 14, 2014

    Eton Pharmaceuticals, Inc. — Marketing Organization

2020s

  1. Jan 6, 2020

    Amta — Marketing Organization

  2. Jan 12, 2024

    Lupin — Marketing Organization

  3. Jan 27, 2026

    Mankind Pharma — Marketing Organization

Indications

Studied for

Mechanism of action

Combination products

  • inderide

    with hydrochlorothiazide

    Also known as inderide la, propranolol hydrochloride & hydrochlorothiazide

Approval history

  • approvedPriority reviewNov 13, 1967

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)NCC(O)COc1cccc2ccccc12
Mol. weight
259.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
  • 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
  • 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
  • 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
  • angilol
  • angilol
  • apsolol
  • apsolol
  • av-83
  • avlocardyl
  • avlocardyl
  • ay-64043
  • ay-64043
  • bedranol
  • bedranol
  • bedranol s.r.
  • berkolol
  • berkolol
  • betadur cr
  • betalong
  • beta-prograne mr
  • beta-propranolol
  • beta-propranolol
  • beta-propranolol
  • cardinol
  • cardinol
  • dl-propranolol
  • dupromex
  • half-beprane cr
  • half-betadur cr
  • half beta-prograne mr
  • half-inderal la
  • half propanix la
  • half propatard la
  • hemangiol
  • ici-45520
  • ici-45520
  • inderal
  • inderal
  • inderal
  • inderal
  • inderal la
  • inderal la
  • inderide-40/25
  • inderide-40/25
  • inderide-80/25
  • inderide-80/25
  • innopran
  • innopran
  • innopran xl
  • innopran xl
  • innopran xl
  • lederpronol
  • lopranol la
  • probeta la
  • propanalol
  • propanalol
  • propanix-10
  • propanix-160
  • propanix-160 sr
  • propanix-40
  • propanix-80
  • propanix la
  • propanolol
  • propanolol
  • propanolol
  • propatard la
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol
  • propranolol cr
  • propranolol hcl
  • propranolol hcl
  • propranolol hcl
  • propranolol hydrochloride
  • propranolol hydrochloride
  • propranolol hydrochloride
  • propranolol hydrochloride
  • propranolol hydrochloride
  • propranolol hydrochloride intensol
  • propranolol hydrochloride intensol
  • propranololo
  • propranololo
  • propranololum
  • propranololum
  • racemic propranolol
  • rapranol sr
  • sagittol
  • sagittol
  • slo-blok
  • slo-pro
  • sloprolol
  • sloprolol
  • syprol
  • tesnol
  • tesnol
  • β-propranolol
  • β-propranolol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07271485Early Phase 1 (Phase 1)Dec 19, 2025Bloom Mental Health, LLC
NCT07311915N/ADec 1, 2025Southeast University
NCT07091279Phase 2Nov 22, 2025Columbia University, Department of Defense, State of New York
NCT06870370Phase 3Sep 20, 2025Tanta University
NCT07067853N/ASep 1, 2025University of Indonesia
NCT07147972Phase 3Aug 20, 2025Fayoum University
NCT06972056Phase 4Jul 9, 2025AbbVie, Mayo Clinic, Patient-Centered Outcomes Research Institute, University of Iowa
NCT06960850N/AJun 1, 2025Federal Teaching Hospital Abakaliki
NCT06982183Phase 4May 27, 2025United States Army
NCT06839144Phase 2Mar 12, 2025National Cancer Institute (NCI), Tel Aviv University
NCT06833320Phase 1/Phase 2 (Phase 2)Mar 1, 2025Columbia University, Department of Defense
NCT06836856Phase 1/Phase 2 (Phase 2)Feb 28, 2025Mansoura University
NCT06787066Early Phase 1 (Phase 1)Feb 28, 2025University of Missouri
NCT06798363Phase 1/Phase 2 (Phase 2)Feb 1, 2025Sichuan University
NCT06719804Early Phase 1 (Phase 1)Dec 5, 2024Capital Medical University, Peking University
NCT06775080Phase 2Dec 1, 2024Fudan University
NCT06670976Phase 1Nov 15, 2024State University of New York, Buffalo
NCT06499116Phase 4Oct 31, 2024Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Català de la Salut, University of Barcelona
NCT06445166Phase 2Oct 31, 2024Washington University in St. Louis
NCT06422494N/ASep 30, 2024Radboud University
Showing 20 of 321 trials
Page 1 / 17

Organizations

Research & Development (270)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institutes of Health (NIH)Government10051997
McGill UniversityAcademic/Hospital9932010
Harvard UniversityAcademic/Hospital8621977
Ain Shams UniversityAcademic/Hospital7752015
Columbia UniversityAcademic/Hospital7732012
National Institute on Drug Abuse (NIDA)Government7231987
State University of New York, BuffaloAcademic/Hospital7632015
University of MissouriAcademic/Hospital7722015
Duke UniversityAcademic/Hospital6432010
Govind Ballabh Pant Institute of Postgraduate Medical Education and ResearchAcademic/Hospital6622002
Hebrew UniversityAcademic/Hospital6432010
Sichuan UniversityAcademic/Hospital6632013
Taipei Veteran General hospitalGovernment6622009
The University of Texas, DallasAcademic/Hospital6011977
Vanderbilt UniversityAcademic/Hospital6531996
Department of DefenseGovernment5032012
Department of Veteran AffairsGovernment5131977
National Cancer Institute (NCI)Government5022017
National Heart, Lung, and Blood Institute (NHLBI)Government5241977
National Institute of Mental Health (NIMH)Government5332001
270 organizations
Page 1 / 14

Marketing (67)

OrganizationOrg typeRelationshipDate
ANDA RepositoryFor profitMKTGOct 22, 1985
ActavisFor profitMKTGMay 15, 1986
Adare PharmaceuticalsFor profitMKTGJul 15, 2011
AiPing Pharm IncFor profitMKTGOct 22, 1986
Akrimax PharmaceuticalsFor profitNDA2Sep 4, 1973
Allied Pharmaceutical ServicesFor profitMKTGFeb 26, 2003
American Home ProductsFor profitNDA2Jul 3, 1985
American Home ProductsFor profitNDA
American Home ProductsFor profitMKTGJun 15, 1979
AmiciFor profitMKTGAug 4, 1986
AmtaFor profitMKTGJan 6, 2020
Ani PharmaceuticalsFor profitNDA2Apr 19, 1983
Ani PharmaceuticalsFor profitMKTGApr 19, 1983
Athenex, Inc.For profitMKTGAug 29, 2000
BaxaltaFor profitNDA2Nov 13, 1967
Boehringer IngelheimFor profitMKTGJul 7, 1986
Chartwell PharmaceuticalsFor profitMKTGAug 29, 2000
Chartwell PharmaceuticalsFor profitSYNJun 13, 1986
DAVA PharmaceuticalsFor profitMKTGJul 30, 1985
Duramed ResearchFor profitMKTGSep 9, 1985
EXTROVISFor profitMKTGFeb 15, 2007
Endo PharmaceuticalsFor profitMKTGApr 14, 1986
Eton Pharmaceuticals, Inc.For profitMKTGMar 14, 2014
FosunFor profitMKTGFeb 26, 2003
FosunFor profitSYNJun 13, 1986
FreseniusFor profitMKTGAug 31, 2001
HikmaFor profitMKTGJan 31, 2008
HikmaFor profitSYNMay 15, 1987
HikmaFor profitSYNMay 15, 1987
IPCA Laboratories Ltd.For profitMKTGJun 2, 2008
Impax LaboratoriesFor profitMKTGApr 6, 1988
InnogenixFor profitMKTGOct 22, 1985
InterpharmFor profitMKTGMay 5, 1987
Inwood LaboratoriesFor profitMKTGApr 11, 1989
LederleFor profitMKTG
LupinFor profitMKTGJan 12, 2024
LupinFor profitSYNJan 12, 2024
Mankind PharmaFor profitMKTGJan 27, 2026
MylanFor profitMKTGNov 19, 1985
Nortec Dev AssocFor profitMKTGJan 26, 2007
Northstar HealthcareAcademic/HospitalMKTGJan 10, 2008
PH HEALTHFor profitMKTGApr 14, 1986
Par PharmaceuticalsFor profitMKTGOct 22, 1986
Pharmaceutical AssociatesFor profitMKTG
Pierre FabreFor profitNDA2Mar 14, 2014
Pierre FabreFor profitMKTGMar 14, 2014
Puracap PharmaceuticalFor profitMKTG
R.P. SchererFor profitMKTGJul 15, 2011
Rising PharmaceuticalsFor profitMKTGApr 1, 1987
Roxane LaboratoriesFor profitMKTGMay 15, 1987
SOLOPAKFor profitMKTG
SandozFor profitMKTG
ScheringFor profitMKTGAug 6, 1985
Schering-PloughFor profitMKTGAug 6, 1985
Smith & NephewFor profitMKTG
Strides Pharma ScienceFor profitMKTGOct 22, 1986
SuperpharmFor profitMKTGJun 8, 1988
TevaFor profitSYNJun 23, 1986
TevaFor profitMKTGApr 11, 1986
Upsher-Smith LaboratoriesFor profitMKTGMar 6, 2009
VintageFor profitMKTGApr 14, 1986
Warner ChilcottFor profitMKTGJan 26, 1988
Watson PharmaceuticalsFor profitMKTGApr 18, 1986
West-Ward PharmaceuticalFor profitMKTGMay 15, 1987
WyethFor profitNDA2Nov 13, 1967
WyethFor profitSYNJun 15, 1979
Zydus Discovery DMCCFor profitMKTGMar 25, 2011